Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation (2011 - 2026)

Tonix Pharmaceuticals Holding's Share-based Compensation history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 123.36% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 79.06% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, up 157.43% from the prior year.
• Share-based Compensation improved to $2.0 million in Q1 2026 per TNXP's latest filing, from $1.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $2.8 million in Q2 2022 and bottomed at $29000.0 in Q1 2023.
• The 5-year median for Share-based Compensation is $1.8 million (2025), against an average of $1.6 million.
• Biggest YoY gain for Share-based Compensation was 5734.48% in 2024; the steepest drop was 56.13% in 2024.
• Year by year, Share-based Compensation stood at $2.7 million in 2022, then declined by 24.96% to $2.0 million in 2023, then sank by 56.13% to $894000.0 in 2024, then jumped by 100.11% to $1.8 million in 2025, then rose by 10.12% to $2.0 million in 2026.
• Per Business Quant, the three latest TNXP Share-based Compensation figures stand at $2.0 million (Q1 2026), $1.8 million (Q4 2025), and $1.9 million (Q3 2025).